Thomas Lingelbach, Valneva CEO

Pfiz­er nabs $95M stake in Val­ne­va as Ly­me dis­ease vac­cine ap­proach­es piv­otal study

Pfiz­er is in­vest­ing some mon­ey in its Ly­me dis­ease part­ner biotech as the pair gears up for a Phase III study.

The Big Phar­ma chipped in $95 mil­lion in eq­ui­ty for Val­ne­va, good enough for an 8.1% stake in the French vac­cine mak­er. Mon­day’s deal comes af­ter the two com­pa­nies ini­tial­ly agreed to de­vel­op the can­di­date in April 2020 and a few months af­ter the pro­gram read out Phase II pe­di­atric re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.